A Phase 3 interventional study of Moxidex otic solution and Moxifloxacin otic solution in Acute Otitis Media, sponsored by Alcon Research. Terminated at 1 site in United States. Open to participants aged 6 Months to 12 Years. Per ClinicalTrials.gov, last updated 2012-12-03.
Sponsored by Alcon Research (part of Alcon) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Otitis Media by Alcon — none open to participants now, none under way, none of them phase 3. Otitis Media · Alcon.
Among the 10 studies in Otitis Media by Alcon, this one is the only one that started in 2010, is one of 5 in phase 3, and was the 5th registered.
241 studies on the registry are indexed under Otitis Media; 32 are open to participants now.
Browse Otitis Media studies →None of the 10 studies in Otitis Media by Alcon is open now. The open studies under Otitis Media, anywhere →
Of the 20 Otitis Media studies recruiting now, 5 (25%) set no upper age limit and 15 (75%) stop at 75 or younger; 19 take children under 18; 4 take healthy volunteers.
This study: 6 Months to 12 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 400 is above the median of 165 across 174 interventional studies indexed under Otitis Media.
Median enrollment 400 across the 9 interventional studies, 318 across the 1 observational. Of the 9 that completed or were terminated, 4 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Alcon Research, one of the names counted as Alcon. Under that name alone:
Alcon Research is the lead sponsor of 624 studies on the registry; 9 are open to participants now.
Of its 112 completed or terminated interventional studies of FDA-regulated products, 102 (91%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Otitis Media by Alcon, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if Moxidex otic solution is safe and effective in treating middle ear infections in patients with ear tubes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Moxidex otic solution
Drug: Moxidex otic solution · Device: Tympanostomy tubes
Moxifloxacin otic solution
Drug: Moxifloxacin otic solution · Device: Tympanostomy tubes
Vehicle
Other: Vehicle · Device: Tympanostomy tubes
Drug pages: Moxifloxacin · Dexamethasone phosphate
4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media in children
Clinical Cure at End of Treatment
Time frame: Day 8
Time to Cessation of Otorrhea
Time frame: From First Dose
Microbiological Success at End of Treatment
Time frame: Day 8
The record gives a start of Feb 2010, a primary completion of Oct 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Moxifloxacin · Dexamethasone phosphate